title: [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
abstract: Antiandrogen therapy has an important role in the treatment of patients with benign prostatic hypertrophy who lack indication for surgery. Herein, the effects on lipid metabolism of administration of antiandrogen agents for benign prostatic hypertrophy are reported. Eighty patients with benign prostatic hypertrophy were each treated with the antiandrogen agents, chlormadinone acetate, allylestrenol, gestonolone caproate and oxendolone for 12 months. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), alpha-lipoprotein, apoprotein, and maronediardehyde (MDA) were measured every 4 weeks after initiation of antiandrogen treatment. In the chlormadinone acetate group, the TG level was significantly decreased between 3 and 6 months after treatment (p < 0.05). In the oxendolone group, the alpha-lipoprotein level was also elevated between 3 and 6 months and between 6 to 12 months after treatment (p < 0.05). The MDA level was also significantly elevated 6 and 12 months after treatment. However, the levels of the other lipids were within the normal range. In conclusion, the changes in the levels of plasma lipoprotein, apoprotein and MDA resulting from antiandrogen therapy were unlikely to be a cause of ischemic coronary disease.
authors.affiliation: Department of Urology, Showa University, Fujigaoka Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Iguchi
authors.forename: T
authors.initials: T
authors.lastname: Ikeuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kai
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000500:Allylestrenol / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002715:Chlormadinone Acetate / Q000627:therapeutic use; D005866:Gestonorone Caproate / Q000627:therapeutic use; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D008055:Lipids; D008075:Lipoproteins, HDL; D002715:Chlormadinone Acetate; D008315:Malondialdehyde; D009277:Nandrolone; D000500:Allylestrenol; C005671:oxendolone; D005866:Gestonorone Caproate